AstraZeneca's Calquence Steps Up in First-Line CLL
Full Results Of First-Line Calquence Use In CLL
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
